TY - JOUR
T1 - The Challenging Experience Questionnaire
T2 - Characterization of challenging experiences with psilocybin mushrooms
AU - Barrett, Frederick S.
AU - Bradstreet, Matthew P.
AU - Leoutsakos, Jeannie Marie S.
AU - Johnson, Matthew W.
AU - Griffiths, Roland R.
N1 - Funding Information:
This research was supported by NIH grants RO1DA03889 and 5T32 DA007209 and grants from the Heffter Research Institute and the Council on Spiritual Practices.
Publisher Copyright:
© The Author(s) 2016.
PY - 2016/12/1
Y1 - 2016/12/1
N2 - Acute adverse psychological reactions to classic hallucinogens ("bad trips" or "challenging experiences"), while usually benign with proper screening, preparation, and support in controlled settings, remain a safety concern in uncontrolled settings (such as illicit use contexts). Anecdotal and case reports suggest potential adverse acute symptoms including affective (panic, depressed mood), cognitive (confusion, feelings of losing sanity), and somatic (nausea, heart palpitation) symptoms. Responses to items from several hallucinogen-sensitive questionnaires (Hallucinogen Rating Scale, the States of Consciousness Questionnaire, and the Five-Dimensional Altered States of Consciousness questionnaire) in an Internet survey of challenging experiences with the classic hallucinogen psilocybin were used to construct and validate a Challenging Experience Questionnaire. The stand-alone Challenging Experience Questionnaire was then validated in a separate sample. Seven Challenging Experience Questionnaire factors (grief, fear, death, insanity, isolation, physical distress, and paranoia) provide a phenomenological profile of challenging aspects of experiences with psilocybin. Factor scores were associated with difficulty, meaningfulness, spiritual significance, and change in well-being attributed to the challenging experiences. The factor structure did not differ based on gender or prior struggle with anxiety or depression. The Challenging Experience Questionnaire provides a basis for future investigation of predictors and outcomes of challenging experiences with classic hallucinogens.
AB - Acute adverse psychological reactions to classic hallucinogens ("bad trips" or "challenging experiences"), while usually benign with proper screening, preparation, and support in controlled settings, remain a safety concern in uncontrolled settings (such as illicit use contexts). Anecdotal and case reports suggest potential adverse acute symptoms including affective (panic, depressed mood), cognitive (confusion, feelings of losing sanity), and somatic (nausea, heart palpitation) symptoms. Responses to items from several hallucinogen-sensitive questionnaires (Hallucinogen Rating Scale, the States of Consciousness Questionnaire, and the Five-Dimensional Altered States of Consciousness questionnaire) in an Internet survey of challenging experiences with the classic hallucinogen psilocybin were used to construct and validate a Challenging Experience Questionnaire. The stand-alone Challenging Experience Questionnaire was then validated in a separate sample. Seven Challenging Experience Questionnaire factors (grief, fear, death, insanity, isolation, physical distress, and paranoia) provide a phenomenological profile of challenging aspects of experiences with psilocybin. Factor scores were associated with difficulty, meaningfulness, spiritual significance, and change in well-being attributed to the challenging experiences. The factor structure did not differ based on gender or prior struggle with anxiety or depression. The Challenging Experience Questionnaire provides a basis for future investigation of predictors and outcomes of challenging experiences with classic hallucinogens.
KW - Psilocybin
KW - challenging experiences
KW - factor analysis
KW - psychedelics
KW - scale development
UR - http://www.scopus.com/inward/record.url?scp=85000963140&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85000963140&partnerID=8YFLogxK
U2 - 10.1177/0269881116678781
DO - 10.1177/0269881116678781
M3 - Article
C2 - 27856683
AN - SCOPUS:85000963140
SN - 0269-8811
VL - 30
SP - 1279
EP - 1295
JO - Journal of Psychopharmacology
JF - Journal of Psychopharmacology
IS - 12
ER -